|
See related MabCampath inj information |
|
|
|
Manufacturer |
Genzyme |
|
Distributor |
Hong Kong: DKSH |
|
Contents |
Alemtuzumab |
|
Indications |
Treatment of patients w/ chronic lymphocytic leukaemia (CLL) who have been treated w/ alkylating agents & who have failed to achieve a complete or partial response or achieved only a short remission (<6 mth) following fludarabine phosphate therapy. |
|
Dosage |
Administer in escalating doses during the 1st wk of treatment: 3 mg on day 1, 10 mg on day 2 & 30 mg on day 3 assuming that each dose is well tolerated. Thereafter, a max maintenance dose of 30 mg given 3 times wkly on alternate days can then be used for up to 12 wk. |
|
Contraindications |
Hypersensitivity to murine proteins; active systemic infections; HIV infection; active secondary malignancies; pregnancy & lactation. |
|
Special Precautions |
If therapy is interrupted for >7 days, MabCampath should be reinstituted with gradual dose escalation. Ischaemic heart disease, angina & patients on antihypertensive medication.Premedication w/ steroids, antihistamine & an analgesic may be required to reduce the risk of infusion-related reactions. Anti-infective prophylaxis is recommended. Perform regular complete blood counts & platelet counts & increase frequency in patients who develop cytopenias. Elderly (>65 yr). |
|
Adverse Drug Reactions |
Very common: Rigors, fever, fatigue, anorexia; hypotension; headache; vomiting, nausea, diarrhoea; granulocytopenia, thrombocytopenia, anaemia; sepsis, herpes simplex; pneumonia, dyspnoea; urticaria, rash, pruritus, increased sweating. Common: Inj site reaction; back pain, neutropenic fever, chest pain, pain, mouth oedema, asthenia, malaise, flu-like symptoms, oedema, temp change sensation; HTN, tachycardia, vasospasm, flushing, palpitation; taste loss, tremor, hypoaesthesia, dizziness, hyperkinesia, conjunctivitis, paraesthesia, vertigo; abdominal pain, GI haemorrhage, stomatitis, mucositis, abnormal hepatic function, constipation, dyspepsia, ulcerative stomatitis, flatulence; pancytopenia, leukopenia, lymphopenia, purpura; hyponatraemia, dehydration, decreased wt, hypocalcaemia, thirst; skeletal pain, arthralgia, myalgia; confusion, anxiety, somnolence, depression, insomnia; cytomegalovirus infection, Pneumocystis carinii infection, moniliasis, herpes zoster infection, fungal infection, abscess; pneumonitis, bronchospasm, sinusitis, coughing, hypoxia, upper resp tract infection, bronchitis, pharyngitis, haemoptysis; erythematous rash, bullous eruption; UTI.
View ADR Monitoring Form |
|
Drug Interactions |
Avoid vaccination w/ live viral vaccines at least 12 mth following MabCampath therapy.
View more drug interactions with MabCampath |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
ATC Classification |
L01XC04 - alemtuzumab ; Belongs to the class of monoclonal antibodies antineoplastic agents. Used in the treatment of cancer. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
MabCampath injection |
|
MabCampath 30 mg/1 mL x 3's |
|
|
|
Manufacturer: |
Genzyme |
|
Distributor: |
Hong Kong: DKSH |
|
|
|
|
|
